資源描述：
《玻璃酸鈉聯(lián)合復(fù)方倍他米松注射液治療膝關(guān)節(jié)骨性關(guān)節(jié)炎的臨床療效觀察》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、珈獰顒關(guān)犧縮瞰節(jié)骨岐節(jié)2018-03-2910:29:58中國(guó)現(xiàn)代醫(yī)生2018年6期朱鑫鑫沈金明［摘要］戸的探討玻璃酸鈉聯(lián)合復(fù)方倍他米松注射液治療膝關(guān)節(jié)骨性關(guān)節(jié)炎的臨床療效。方法收集2016年1月?2017年1月我院收治的膝關(guān)節(jié)骨性關(guān)節(jié)炎患者90例作為研究對(duì)象，將納入符合要求患者采用隨機(jī)數(shù)字表法隨機(jī)分成觀察組(n=45)和對(duì)照組(n=45)。兩組均予以玻璃酸鈉關(guān)節(jié)腔內(nèi)注射，觀察組同時(shí)加入復(fù)方倍他米松注射液，兩組均治療5周。治療后對(duì)兩組的臨床療效、臨床癥狀改善情況及膝關(guān)節(jié)功能改善情況進(jìn)行評(píng)價(jià)。結(jié)果觀察組患者治療后的總有效率(
2、97.8%)明顯高于對(duì)照組(77.8%),差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組患者治療前的HSS評(píng)分比較，差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)；治療后HSS評(píng)分與治療前比較明顯升高(P<0.05),觀察組患者治療后HSS評(píng)分顯著高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組患者治療前的臨床癥狀評(píng)分比較，差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),治療后兩組患者臨床癥狀評(píng)分較治療前明顯降低(PvO.05),且觀察組患者治療后的臨床癥狀評(píng)分顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義(PvO.05)。結(jié)論玻璃酸鈉聯(lián)合復(fù)方倍他米松注射液治療膝關(guān)節(jié)骨
3、性關(guān)節(jié)炎臨床療效顯著提高，且患者的臨床癥狀明顯改善，膝關(guān)節(jié)功能明顯提高，值得廣泛推廣和應(yīng)用。［關(guān)鍵詞］膝關(guān)節(jié)骨性關(guān)節(jié)炎；玻璃酸鈉；復(fù)方倍他米松注射液；HSS評(píng)分［中圖分類(lèi)號(hào)］R684.3［文獻(xiàn)標(biāo)識(shí)碼］B［文章編1673-9701(2018)06-0090-04［Abstract］ObjectiveToinvestigatetheclinicalefficacyofsodiumhyaluronatecombinedwithcompoundbetamethasoneinjectioninthetreatmentofkneeos
4、teoarthritis?MethodsAtotalof90patientswithkneeosteoarthritiswhowereadmittedtoourhospitalfromJanuary2016toJanuary2017werecollectedasthestudysubjects.Patientswhowereeligibleforinclusionwererandomlydividedintoobservationgroup(n二45)andcontrolgroup(n=45)viarandomnumber
5、table.Thetwogroupsweregivensodiumhyaluronateintra-articularinjection.Theobservationgroupwasalsogivencompoundbetamethasoneinjection.Bothgroupsweretreatedfor5weeks.Aftertreatment,theclinicalefficacy,improvementofclinicalsymptomsandimprovementofkneejointfunctionweree
6、valuatedinbothgroups?ResultsThetotaleffectiverate(97.8%)inobservationgroupwassignificantlyhigherthanthatincontrolgroup(77.8%),andthecomparativeanalysisoftheefficacyinthetwogroupsshowedsignificantdifferences(P<0.05)?TherewasnostatisticallysignificantdiffereneeinHSS
7、scoresbetweenthetwogroupsbeforetreatment(P>0.05)；aftertreatment,HSSscorewassignificantlyhigherthanthatbeforetreatment(P<0?05)；theHSSscoreintheobservationgroupwassignificantlyhigherthanthatinthecontrolgroupaftertreatment,andthecomparativeanalysisinthetwogroupsshowe
8、dsignificantdifferences(P<0.05).Therewasnostatisticallysignificantdifferenceinclinicalsymptomscoresbetweenthetwogroupsbeforetreatment(P>0.05)；thescoresa
